The team believe the discovery represents a major step towards enabling the design of better treatments for psoriasis, which affects up to a million people in the UK alone (figures from the Psoriasis Association).
The results of the Wellcome Trust-funded study of the drug, dithranol, are published in the Journal of the Federation of American Societies for Experimental Biology (FASEB).
Dithranol, which is widely used in the treatment of psoriasis, is derived from a natural compound, called chrysarobin. Chrysarobin is prepared from the araroba tree found in the rain forests of the Amazon. In India, the same substance is known as Goa powder.
Psoriasis is a genetic condition which, when triggered by certain factors such as injury or throat infection, leads to an over-production of skin cells ¬¬– called keratinocytes – which causes a thickening of the skin, resulting in the raised red, scaly patches characteristic of psoriasis.
The team of scientists, led by Professor Nick Reynolds and Dr Mark Birch-Machin, of the Skin and Environmental Interactions Research Group in the School of Clinical and Laboratory Sciences at Newcastle University, studied the effects of dithranol – an ointment applied to the surface of the skin – which is used in the treatment of severe cases of psoriasis.
Professor Reynolds says: 'Psoriasis is what is known as a relapsing/remitting condition, which means that sufferers don't display the symptoms all of the time. Dithranol is a very effective treatment for episodes of psoriasis and it has been around for a long time, since the early 1900s. By studying the action of the drug, we wanted to gain a better understanding of how it works, to give us an insight into the mechanism of the condition.'
Laboratory studies showed that dithranol very quickly targeted skin cells' mitochondria – the part of a cell from which it draws its energy – causing the cells to die within 24 – 48 hours of the application of the drug, through a process of programmed cell death.
Professor Reynolds continued: 'Although dithranol is a very effective and safe treatment for psoriasis, its widespread use is limited because it is quite difficult to use and causes dark brown stains on clothing and bedding. Also, if it is not used properly, it can cause irritation or burning to the skin around the affected area, so it is most commonly used in hospitals, where the application of the ointment can be overseen by a nurse.'
Most people suffering an episode of psoriasis that requires treatment with dithranol therefore have either to attend hospital as an outpatient five days a week for a six week course of treatment, or be admitted for a three-week period.
'In modern life, this is far from ideal', says Professor Reynolds. 'These findings represent an important step towards the development of better-designed treatments for psoriasis sufferers'.
Gladys Edwards, Chief Executive of the Psoriasis Association said: 'The Psoriasis Association welcomes these new research findings. It is so important to develop new, effective and safe treatments for psoriasis and this research is clearly a positive step forward'.
John Young, 47, from Newcastle upon Tyne, lives with his partner Sharon, a nurse, and their baby son. They met during one of his many stays in hospital to have treatment for his psoriasis. John has suffered from severe psoriasis since the age of nine. Formerly a plasterer, he has retired on health grounds as he now suffers from psoriatic arthritis.
He says: 'Suffering from psoriasis has blighted my life, and at times made me very depressed. For years, it has affected my family life, social life and career prospects, but meeting Sharon has really turned my life around'.
Sharon adds: 'Anything which helps to improve awareness of the condition is a positive step, because people do stare, especially if psoriasis occurs on the face and hands. We welcome this research, because anything new which might lead to more help for people suffering from psoriasis can only be a good thing.'
PSORIASIS FACTFILE (information from the Psoriasis Association)
Psoriasis is a recurrent skin condition caused by an acceleration of the usual replacement processes of the skin. Normally a skin cell matures in 21 to 28 days during its passage to the surface where a constant invisible shedding of dead cells, as scales, takes place. Psoriatic cells, however, are believed to turn over in two to three days and in such profusion that even live cells reach the surface and accumulate with the dead cells in layers. Psoriasis affects both sexes equally. It may appear for the first time at any age, although it is more likely to appear between the ages of 11 and 45.
Psoriasis appears as raised red patches of skin covered with silvery scales. It can occur on any part of the body although elbows, knees and the scalp are usual sites.
Certain genes have been identified as being linked to psoriasis. It appears, however, that a genetic tendency needs to be triggered off by such things as injury, throat infection, certain drugs and physical and emotional stress. Research is under way into all aspects of the causes of psoriasis.
There are a variety of topical treatments available i.e. creams and ointments that are applied to the skin. When used properly they can be most effective and have minimal side effects.
NOTES FOR EDITORS
1. Interviews with Professor Reynolds, Dr Birch-Machin and John Young can be arranged by contacting the University Press Office on 0191 222 5791/7850.
2. The research paper 'The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential and induces apoptosis through a pathway dependent on respiratory competent mitochondria', by Alison McGill, Adrian Frank, Nicola Emmett, Suzanne N Leech, Douglas M Turnbull Mark A Birch-Machin and Nick J Reynolds is published in the June 2005 edition of US-based Journal of the Federation of American Societies for Experimental Biology. A copy of the paper is available in electronic format from the University Press Office, e-mail firstname.lastname@example.org or 0191 222 7850.
3. Dithranol is marketed in the US as anthralin.
USEFUL WEB PAGES:
Newcastle University is committed to bringing about change for the better at international, national and regional level. Its Transforming Horizons document states that the University is committed to transforming health by seeking effective remedies for health problems, educating tomorrow's health professionals and changing thinking about health care.
Issued by the University Press Office. Contact +44 (0)191 222 7850 or e-mail email@example.com
published on: 28th June 2005